Filing status
- Accounts due
- 31 March 2028
- Last accounts
- 30 June 2026
- Conf. stmt due
- 21 January 2027
- Last conf. stmt
- 7 January 2026
Genome Therapeutics Ltd
- Incorporated
- 8 January 2020 (6 years)
- Previously known as
- Inflex Limited (until 15 June 2024)This list may be incomplete. See all names on Companies House
- Industry
- Research and experimental development on biotechnology (72110)
- Directors
- Xiangmin CuiJames Walter GlasheenSamuel Aparicio
- Accounts type
- Small
- Region
- Greater London
- Address
- Regent House316 Beulah HillLondonSE19 3HF
Charges
- Total
- 2
- Outstanding
- 1
- Part satisfied
- 0
- Satisfied
- 1
Officers 6 active
Officer details are public data from the Companies House register.
Cui, Xiangmin, Dr
Director · Appointed 2 December 2025
American
Born August 1968 (58)
Glasheen, James Walter, Dr
Director · Appointed 20 October 2025
American
Born December 1967 (58)
Aparicio, Samuel, Dr
Director · Appointed 14 September 2025
Canadian
Born October 1963 (63)
Director · Appointed 8 August 2025
British
Born October 1970 (56)
Director · Appointed 6 June 2024
British
Born May 1966 (60)
Mchugh, Dan
Director · Appointed 28 April 2022
American,Irish
Born March 1992 (34)
Officer history (4 former)
2 December 2025
Appointed Cui, Xiangmin, Dr as Director
20 October 2025
Appointed Glasheen, James Walter, Dr as Director
14 September 2025
Appointed Aparicio, Samuel, Dr as Director
14 September 2025
8 August 2025
7 January 2025
2 December 2024
Resigned Mahmood, Saiyed Ibraheem as Director
6 June 2024
Appointed Mahmood, Saiyed Ibraheem as Director
6 June 2024
Resigned Aparicio, Samuel, Dr as Director
6 June 2024
28 April 2022
Appointed Aparicio, Samuel, Dr as Director
28 April 2022
Appointed Mchugh, Dan as Director
8 January 2020
8 January 2020
Ownership 0 active
People and entities with significant control, from the Companies House PSC register
The company has declared that it has no person with significant control.
Former controllers (4)
8 August 2025
Ceased Samuel Aparicio — Owns 25–50% of shares
8 August 2025
18 October 2024
Ceased Samuel Aparicio — Owns 25–50% of shares
29 January 2020
Financials
Figures from 2025 accounts. Newer accounts, made up to 30 June 2026, are filed but not read yet. See them on Companies House
- Net Assets
- £364,835
- Cash
- £362,941
- Employees
- 6
- Debt Ratio
- 43%
Trend
Net Assets
Balance sheet detail
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Fixed Assets | £65,800 | £84,397 | £48,408 | £61,908 | |
| Current Assets | £577,055 | £1,945,129 | £2,011,157 | ||
| Debtors | £214,114 | £471,242 | £268,640 | £45,259 | |
| Cash | £362,941 | £1,473,887 | £3,246,655 | £1,965,898 | £18,412 |
| Creditors (< 1 year) | £333,090 | £69,206 | £600 | ||
| Creditors (> 1 year) | £0 | £44,975 | |||
| Net Current Assets | £299,035 | £1,622,657 | £1,941,951 | £17,812 | |
| Net Assets | £364,835 | £1,707,054 | £2,003,859 | (£27,163) | |
| Shareholder Funds | £2,003,859 | (£27,163) |
Filings
Recent filings only. See the full history on Companies House
| Date | Description | Made Up To | Pages | |
|---|---|---|---|---|
| 6 November 2026 | Cancellation of shares | — | ||
| 6 November 2026 | Purchase of own shares | — | ||
| 4 November 2026 | Resolutions | |||
| 1 November 2026 | Accounts for a small company | 30 June 2026 | ||
| 27 October 2026 | Statement of capital following an allotment of shares |
Some other companies at this address
Other companies in this industry
By trade and location
Explore the largest companies
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →